OncoMatch/Clinical Trials/NCT07284927
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
Is NCT07284927 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LV009 for non-hodgkin lymphoma.
Treatment: LV009 — This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression (positive)
confirmed diagnosis of CD19-positive hematolymphoid malignancy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: relapsed or refractory disease
Meets the National Comprehensive Cancer Network (NCCN) criteria for relapsed or refractory disease
Cannot have received: CAR-T cell therapy
Patients who have received CAR-T therapy or other genetically modified cell therapies prior to screening.
Lab requirements
Blood counts
ALC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; CD3-positive T-cell count ≥ 150 cells/μL
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiopulmonary function
Adequate hepatic, renal, and cardiopulmonary function; ALC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; CD3-positive T-cell count ≥ 150 cells/μL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify